Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127159) titled 'A real-world study evaluating the effectiveness of Nirsevimab, a novel antibody drug, for preventing RSV and other respiratory infections in infants in southern China' on June 25.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Guangzhou Women and Children's Medical Center,Guangzhou Medical University
Condition:
Respiratory syncytial virus (RSV)-related respiratory tract infections (including acute bronchitis, bronchiolitis, and pneumonia), all-cause respiratory infections, wheezing episodes.
Intervention:
Nirsevimab exposed Group:None
Recruitment Status: Not Recruiting
Phase:...